Clinical Trial Update: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a circulating tumor DNA–enriched, genomically directed post-neoadjuvant approach for patients with residual triple-negative breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Bryan Schneider, MD | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-05-31